Related papers: Estimating the optimal time to perform a PET-PSMA …
The progress of the prostate-specific antigen after radical prostatectomy is observed for a patient in order to extract information on the growth mode of the tumor cells. An initial fast-growth mode goes over to a slower power-law regime…
Prostate cancer is one of the most common cancers in men. It is characterized by a slow growth and it can be diagnosed in an early stage by observing the Prostate Specific Antigen (PSA). However, a relapse after the primary therapy could…
Active surveillance (AS) is a suitable management option for newly-diagnosed prostate cancer (PCa), which usually presents low to intermediate clinical risk. Patients enrolled in AS have their tumor closely monitored via longitudinal…
In patients with biochemical recurrence of prostate cancer and negative PSMA PET/CT, radiomics features extracted from recurrence-prone organs can predict clinical progression and progression-free survival. In a cohort of 132 patients,…
Prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging provides a tremendously exciting frontier in visualization of prostate cancer (PCa) metastatic lesions. However, accurate…
Prostate cancer patients who undergo prostatectomy are closely monitored for recurrence and metastasis using routine prostate-specific antigen (PSA) measurements. When PSA levels rise, salvage therapies are recommended to decrease the risk…
Low risk prostate cancer patients enrolled in active surveillance (AS) programs commonly undergo biopsies on a frequent basis for examination of cancer progression. AS programs employ a fixed schedule of biopsies for all patients. Such…
Serum prostate-specific antigen (PSA) is widely used for prostate cancer screening. While the genetics of PSA levels has been studied to enhance screening accuracy, the genetic basis of PSA velocity, the rate of PSA change over time,…
Biparametric MRI has emerged as an alternative to multiparametric prostate MRI, which eliminates the need for the potential harms to the patient due to the contrast medium. One major issue with biparametric MRI is difficulty to detect…
Background: Low-risk prostate cancer patients enrolled in active surveillance programs commonly undergo biopsies for examination of cancer progression. Biopsies are conducted as per a fixed and frequent schedule (e.g., annual biopsies).…
Prostate cancer is the most common disease in men and the second leading cause of death from cancer. Generic large imaging instruments used in cancer diagnosis have sensitivity, spatial resolution, and contrast inadequate for the task of…
Prostate cancer is one of the most common types of cancer in men. Its diagnosis by biopsy requires a high level of expertise and precision from the surgeon, so the results are highly operator-dependent. The aim of this work is to develop a…
Background and objective: Micro-ultrasound (micro-US) is a novel imaging modality with diagnostic accuracy comparable to MRI for detecting clinically significant prostate cancer (csPCa). We investigated whether artificial intelligence (AI)…
Prostate cancer (PCa) is the most frequently diagnosed malignancy in men and the eighth leading cause of cancer death worldwide. Multiparametric MRI (mpMRI) has become central to the diagnostic pathway for men at intermediate risk,…
We use a Stochastic Hybrid Automaton (SHA) model of prostate cancer evolution under intermittent androgen suppression (IAS) to study a threshold-based policy for therapy design. IAS is currently one of the most widely used treatments for…
Prostate cancer (Pca) continues to be a leading cause of cancer-related mortality in men, and the limitations in precision of traditional diagnostic methods such as the Digital Rectal Exam (DRE), Prostate-Specific Antigen (PSA) testing, and…
Prostate cancer (PCa) poses a significant threat to men's health, with early diagnosis being crucial for improving prognosis and reducing mortality rates. Transrectal ultrasound (TRUS) plays a vital role in the diagnosis and image-guided…
The purpose was to investigate the spatial heterogeneity of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) uptake within parotid glands. We aim to quantify patterns in well-defined regions to facilitate further…
Joint modelling of longitudinal and survival data is increasingly used in clinical trials on cancer. In prostate cancer for example, these models permit to account for the link between longitudinal measures of prostate-specific antigen…
Proton therapy's full potential is limited by uncertainties that prevent optimal dose distribution. Monitoring techniques can reduce these uncertainties and enable adaptive treatment planning. Spatiotemporal Emission Reconstruction from…